Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Azienda Ospedaliero-Universitaria Careggi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age\> 18 years
* Ability to express informed consent
Histological or cytological diagnosis (possibility of PDL-1 determination) of NSCLC
\- Brain metastases up to a maximum of 10 and all treated with RS or Hypofractionated stereotactic radiotherapy (3 to 5 fractions)
Brain disease assessable according to iRANO criteria
Radiation therapy on brain metastases within 4 weeks before or after infusion of immunotherapy in the following settings
brain metastases at initio brain metastases treated with RS + 1st line therapy
Brain metastases as I progression after I line of systemic therapy CHT, IT or CHTIT regardless of whether or not the same line is continued (treatment Beyond progression) or shift to the next line;
Brain metastases as II progression after II line of systemic therapy (CHT, IT) regardless of whether it is continued or not of the same line (treatment beyond progression) or shift to the next line.
Diagnostic brain MRI for brain metastases within one month of treatment stereotactic
Esclusion criteria:
Life expectancy of less than 6 months (calculated with GPA score \<2)
Performance Status\> 2
Previous radiotherapy treatment at the brain site
Contraindication to MRI of the brain with contrast medium
Presence of a number of intracranial metastases\> 10
Inability to express informed consent
Infusion of immunotherapy more than 4 weeks before and after radiotherapy
Impossibility of recording times and dosages of administration of steroid therapy
